Spinal Cord Stimulation for Small Fiber Neuropathy

(SAL SFN PILOT Trial)

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: TriCity Research Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This prospective observational pilot study will evaluate structural, functional, and patient-reported outcomes in adults with small fiber neuropathy who receive Saluda Evoke ECAP-controlled spinal cord stimulation as part of routine clinical care. The study does not assign, direct, or modify spinal cord stimulation therapy. All decisions regarding patient selection, trial stimulation, permanent implantation, and device programming are made independently by the treating physician according to standard clinical practice.

The primary objective is to assess change in intra-epidermal nerve fiber density from baseline to 12 months. Secondary objectives include evaluation of quantitative sensory testing, pain intensity, patient-reported outcomes, and correlations between changes in nerve fiber density, sensory function, and neuropathic pain outcomes.

The study will enroll up to 10 adult participants with clinically diagnosed small fiber neuropathy and chronic neuropathic pain. Research assessments include patient-reported outcome measures, quantitative sensory testing, review of available clinical records, and a 12-month follow-up skin biopsy for intra-epidermal nerve fiber density.

This aligns with the approved protocol: observational, 10 adults, 12-month participant follow-up, primary IENFD endpoint, and secondary QST/pain/correlation endpoints.

Who Is on the Research Team?

PB

Pravardhan Birthi, M.D.

Principal Investigator

TriCity Research Center, LLC

MP

Mahesh Pattabiraman, Ph.D.

Principal Investigator

TriCity Research Center

Are You a Good Fit for This Trial?

This study is for adults diagnosed with small fiber neuropathy and chronic nerve pain who are already receiving spinal cord stimulation as part of their regular care. Participants must be able to complete follow-up visits over a year.

Inclusion Criteria

I have been diagnosed with small fiber neuropathy by a skin biopsy.
I am 19 years old or older.
I am considered suitable for ECAP-controlled spinal cord stimulation therapy.
See 4 more

Exclusion Criteria

Uncontrolled medical or psychiatric conditions
I do not have any conditions that prevent me from receiving spinal cord stimulation therapy.
Pregnancy or planning to become pregnant during the study period
See 1 more

What Are the Treatments Tested in This Trial?

Interventions

  • Evoke ECAP-controlled spinal cord stimulation

Trial Overview

The study observes changes in skin nerve fibers, pain levels, and sensory function over 12 months in people using the Evoke spinal cord stimulator. No new treatments or changes to therapy are made; all care decisions remain with each person's doctor.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Saluda Evoke ECAP-Controlled Spinal Cord Stimulation SystemExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

TriCity Research Center

Lead Sponsor

Saluda Medical Americas, Inc.

Industry Sponsor

Trials
2
Recruited
160+